The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: A randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+)
Salah‐Eddin Al‐Batran(Goethe University Frankfurt), Elke Jäger(Krankenhaus Nordwest), Stephan Probst(Klinikum Bielefeld), Jan Stoehlmacher-Williams, Markus Moehler(Johannes Gutenberg University Mainz), Nicole Prasnikar(Asklepios Klinik Barmbek), Rolf Mahlberg(Klinikum Mutterhaus der Borromäerinnen), Ralf‐Dieter Hofheinz(University of Mannheim), Kim Barbara Luley(University Hospital Schleswig-Holstein), Volker Rethwisch(Klinikum Dortmund), Carsten Bokemeyer(Universität Hamburg), Stephan Hollerbach(Heidelberg University), Jörg T. Hartmann(University of Tübingen), Claudia Pauligk(Goethe University Frankfurt), Frank Kullmann(Klinikum Weiden), Nils Homann(Fraunhofer Project Centre Wolfsburg)
Cited by 167
Related Papers
Autopsy Findings and Venous Thromboembolism in Patients With COVID-19
|Annals of Internal Medicine|2020|2.4k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
|New England Journal of Medicine|2021|1.7k